Actively Recruiting
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Led by Wei Zhao · Updated on 2025-03-30
1500
Participants Needed
2
Research Sites
569 weeks
Total Duration
On this page
Sponsors
W
Wei Zhao
Lead Sponsor
C
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
CONDITIONS
Official Title
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be diagnosed with hematological neoplasms
- Antineoplastic drugs or anti-infective drugs used as part of regular treatment
You will not qualify if you...
- Expected survival time less than the treatment cycle
- Patients with other factors that researcher considers unsuitable for inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China, 221000
Completed
2
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tanjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
W
Wei Zhao, Ph.D
CONTACT
Y
Yan H Shi, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here